RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. RXi Pharmaceuticals Corporation has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone508-767-3861
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10,000.00
Profitability
Miscellaneous
Employees15
OptionableNot Optionable
RXi Pharmaceuticals (NASDAQ:RXII) Frequently Asked Questions
What is RXi Pharmaceuticals' stock symbol?
RXi Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXII."
When did RXi Pharmaceuticals' stock split? How did RXi Pharmaceuticals' stock split work?
RXi Pharmaceuticals's stock reverse split on the morning of Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of RXi Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were RXi Pharmaceuticals' earnings last quarter?
RXi Pharmaceuticals Corp (NASDAQ:RXII) released its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.02 million. RXi Pharmaceuticals had a negative return on equity of 412.15% and a negative net margin of 4,990.20%. View RXi Pharmaceuticals' Earnings History.
When is RXi Pharmaceuticals' next earnings date?
What price target have analysts set for RXII?
1 analysts have issued 1-year target prices for RXi Pharmaceuticals' stock. Their predictions range from $3.00 to $3.00. On average, they expect RXi Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Price Targets for RXi Pharmaceuticals.
What is the consensus analysts' recommendation for RXi Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RXi Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RXi Pharmaceuticals.
Has RXi Pharmaceuticals been receiving favorable news coverage?
News headlines about RXII stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. RXi Pharmaceuticals earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are some of RXi Pharmaceuticals' key competitors?
Some companies that are related to RXi Pharmaceuticals include Stellar Biotechnologies (SBOT), OHR Pharmaceutical (OHRP), Praxsyn (PXYN), Boston Therapeutics (BTHE), Immune Therapeutics (IMUN), Sonoma Pharmaceuticals (SNOA), Parnell Pharmaceuticals (PARNF), Propanc Biopharma (PPCB), Acura Pharmaceuticals (ACUR), ContraVir Pharmaceuticals (CTRV), Bioblast Pharma (ORPN), Integrated BioPharma (INBP), Midatech Pharma (MTP), Ritter Pharmaceuticals (RTTR) and iCo Therapeutics (ICOTF).
Who are RXi Pharmaceuticals' key executives?
RXi Pharmaceuticals' management team includes the folowing people:
- Dr. Geert Cauwenbergh, Pres, CEO, Acting CFO & Director (Age 64)
- Dr. Gerrit Dispersyn Dr. Med. Sc, Chief Devel. Officer (Age 43)
- Ms. Caitlin Kontulis, Sr. Director of Fin. & Sec. (Age 32)
- Dr. Karen Bulock, Former VP of Research
How do I buy shares of RXi Pharmaceuticals?
Shares of RXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is RXi Pharmaceuticals?
RXi Pharmaceuticals has a market capitalization of $0.00 and generates $10,000.00 in revenue each year. The biotechnology company earns $-12,450,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis. RXi Pharmaceuticals employs 15 workers across the globe.
What is RXi Pharmaceuticals' official website?
How can I contact RXi Pharmaceuticals?
RXi Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The biotechnology company can be reached via phone at 508-767-3861 or via email at [email protected]
MarketBeat Community Rating for RXi Pharmaceuticals (NASDAQ RXII)
MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals and other stocks. Vote "Outperform" if you believe RXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
